Lynd, Larry D.; Goeree, Ron; O'Brien, Bernie J. - In: PharmacoEconomics 23 (2005) 11, pp. 1083-1106
The economic burden of influenza-related illness has been estimated to be $US71.3-166 billion in the US, the majority of which is attributable to indirect costs as a result of lost productivity. There are currently four antiviral drugs available for the treatment of influenza: two ion channel...